Indomethacin
NDC Package 66336-687-30

11-digit billing NDC: 66336068730

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Indomethacin is carefully consider the potential benefits and risks of Indomethacin Extended-Release Capsules, USP and other treatment options before deciding to use Indomethacin Extended-Release Capsules, USP. Marketed by Dispensing Solutions, Inc., this product is identified by NDC 66336-687 and is authorized under FDA application ANDA091549.

Identification & Billing

NDC Package Code
66336-687-30
Package Description
30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
66336068730
RxNorm Crosswalk
RxCUI: 310992 - indomethacin 75 MG Extended Release Oral Capsule

Clinical Specifications

Proprietary Name
Indomethacin
Dosage Form
-
Usage Information
Carefully consider the potential benefits and risks of Indomethacin Extended-Release Capsules, USP and other treatment options before deciding to use Indomethacin Extended-Release Capsules, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS).Indomethacin Extended-Release Capsules, USP have been found effective in active stages of the following:1. Moderate to severe rheumatoid arthritis including acute flares of chronic disease.2. Moderate to severe ankylosing spondylitis.3. Moderate to sever osteoarthritis.4. Acute painful shoulder (bursitis and/or tendonitis).Indomethacin Extended-Release Capsules, USP are not recommended for the treatment of acute gouty arthritis.Indomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more sever forms of rheumatoid arthritis. In such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effects.The use of indomethacin in conjunction with aspirin or other salicylates is not recommended. Controlled clinical studies have shown that the combined use of indomethacin and aspirin does not product any greater therapeutic effect than the use of indomethacin alone. Furthermore, in one of these clinical studies, the incidence of gastrointestinal side effects was significantly increased with combined therapy. (see PRECAUTIONS, Drug Interactions).

Regulatory & Marketing

Labeler Name
Dispensing Solutions, Inc.
FDA Application #
ANDA091549
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-06-2010
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 66336-687-30 identifies a specific commercial package of 30 capsule, extended release in 1 bottle of Indomethacin, labeled by Dispensing Solutions, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Dispensing Solutions, Inc. on December 06, 2010. The current certification is valid through December 31, 2017.

How is this Dispensing Solutions, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 66336068730. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
66336-687-30
11-Digit CMS (5-4-2)
66336-0687-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.